A Phase Ib/II Study of MEK162 in Combination With Imatinib Mesylate in Patients With Untreated Advanced Gastrointestinal Stromal Tumor (GIST)

Trial Profile

A Phase Ib/II Study of MEK162 in Combination With Imatinib Mesylate in Patients With Untreated Advanced Gastrointestinal Stromal Tumor (GIST)

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 03 Sep 2016

At a glance

  • Drugs Binimetinib (Primary) ; Imatinib
  • Indications Gastrointestinal stromal tumours
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 02 Jun 2015 Interim results for the phase I portion presented at the 51st Annual Meeting of the American Society of Clinical Oncology.
    • 02 Jun 2015 The phase I portion has been completed in 18 patients and the phase II portion is underway, as reported at the 51st Annual Meeting of the American Society of Clinical Oncology.
    • 04 May 2015 According to Array BioPharma media release, data from this trial is expected at American Society of Clinical Oncology (ASCO).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top